139 related articles for article (PubMed ID: 35578939)
21. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
[TBL] [Abstract][Full Text] [Related]
22. Abemaciclib and Fulvestrant for Bilateral Choroidal Metastasis From Breast Carcinoma.
Barke MR; Agrawal KU; Shields CL
JAMA Ophthalmol; 2022 Oct; 140(10):1026-1028. PubMed ID: 36074499
[TBL] [Abstract][Full Text] [Related]
23. Peritoneal Metastasis After Treated With Abemaciclib Plus Fulvestrant for Metastatic Invasive Lobular Breast Cancer: A Case Report and Review of the Literature.
Gao HF; Zhang JS; Zhang QZ; Zhu T; Yang CQ; Zhang LL; Yang M; Ji F; Li JQ; Cheng MY; Niu G; Wang K
Front Endocrinol (Lausanne); 2021; 12():659537. PubMed ID: 34690920
[TBL] [Abstract][Full Text] [Related]
24. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
25. [A Case of Recurrent Breast Cancer with Multiple Bone Metastasis Effectively Treated by CDK4/6 Inhibitor in Addition to Aromatase Inhibitor].
Satoh E; Hara M; Uehira D; Yonekura K; Murakata A; Ohinata R; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1491-1493. PubMed ID: 36733112
[TBL] [Abstract][Full Text] [Related]
26. [A Case of Advanced Late Recurrence of Hormone Receptor Positive Breast Cancer Successfully Treated with Abemaciclib and Anastrozole].
Minamoto K; Ikeda T; Araki K; Hamada M
Gan To Kagaku Ryoho; 2021 Oct; 48(10):1259-1263. PubMed ID: 34657059
[TBL] [Abstract][Full Text] [Related]
27. [Ethinylestradiol Following Everolimus plus Exemestane Was Effective in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer - A Case Report].
Matsuoka A; Hirano A; Hattori A; Ogura K; Inoue H; Yukawa H; Sakaguchi S; Tanaka N; Kodera A; Kamimura M; Naritaka Y; Shimizu T
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1219-1222. PubMed ID: 27760942
[TBL] [Abstract][Full Text] [Related]
28. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
[TBL] [Abstract][Full Text] [Related]
29. [A Case of Multiple Lung Metastases from Breast Cancer Successfully Treated with Endocrine Therapy].
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Noda S; Takashima T; Onoda N; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2426-2428. PubMed ID: 30692486
[TBL] [Abstract][Full Text] [Related]
30. [Long-Term Effect of Fulvestrant for Locally Advanced Breast Cancer in an Elderly Patient - A Case Report].
Sakurai K; Fujisaki S; Kubota H; Hara Y; Suzuki S; Adachi K; Tomita R; Enomoto K; Hirano T
Gan To Kagaku Ryoho; 2018 Jan; 45(1):76-78. PubMed ID: 29362313
[TBL] [Abstract][Full Text] [Related]
31. CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Huang HW; Huang LS; Xu QN; Wang HB; Li XY; Lin JZ
Medicine (Baltimore); 2019 Jan; 98(1):e13909. PubMed ID: 30608416
[TBL] [Abstract][Full Text] [Related]
32. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
33. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Lainé M; Fanning SW; Chang YF; Green B; Greene ME; Komm B; Kurleto JD; Phung L; Greene GL
Breast Cancer Res; 2021 May; 23(1):54. PubMed ID: 33980285
[TBL] [Abstract][Full Text] [Related]
34. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
[TBL] [Abstract][Full Text] [Related]
35. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
36. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
37. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
38. Current frontline endocrine treatment options for women with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced-stage breast cancer.
Abdel-Razeq H
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):1-9. PubMed ID: 29792845
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Carlson RW; O'Neill A; Vidaurre T; Gomez HL; Badve SS; Sledge GW
Breast Cancer Res Treat; 2012 Jun; 133(3):1049-56. PubMed ID: 22418699
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
du Rusquec P; Palpacuer C; Campion L; Patsouris A; Augereau P; Gourmelon C; Robert M; Dumas L; Caroline F; Campone M; Frenel JS
Breast Cancer Res Treat; 2018 Apr; 168(2):559-566. PubMed ID: 29247442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
